DGIdb - DACLIZUMAB Drug Record

DACLIZUMAB chembl:CHEMBL1201605 ApprovedImmunotherapy

Alternate Names:

ZINBRYTA
ZENAPAX
DACLIZUMAB
DACLIZUMAB BETA
RO-24-7375
IG GAMMA-1 CHAIN C REGION
ANTI-IL-2
HUMANIZED ANTICD25
drugbank:00111
rxcui:190353
chemidplus:152923-56-3
chembl:CHEMBL1201605

Drug Info:

Year of Approval	1997
Drug Class	immunosuppressive agents
FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	immunosuppressant

(1 More Sources)

Publications:

Garcia et al., Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis., Transplant. Proc.
Monti et al., 2009, Disengaging the IL-2 receptor with daclizumab enhances IL-7-mediated proliferation of CD4(+) and CD8(+) T cells., Am. J. Transplant.
Shamsi et al., 2005, Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report., J Pak Med Assoc
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Krouwels et al., 1996, Glucocorticosteroids affect functions of airway- and blood-derived human T-cell clones, favoring the Th1 profile through two mechanisms., Am. J. Respir. Cell Mol. Biol.
Przepiorka et al., 2000, Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease., Blood
Patlolla et al., 2007, Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation., Am. J. Transplant.
Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.
Aguillón et al., 2003, [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]., Rev Med Chil
Light et al., 2002, Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation., Clin Transplant
Ramos et al., 1989, Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody., Transplantation
Burkhardt et al., 1989, Anti-IL-2 receptor monoclonal antibody AMT-13 increases soluble IL-2 receptor levels in vivo., Immunology

DACLIZUMAB IL2RB

Interaction Score: 21.64

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
15814281 15022409 12372041 2571203 11752352 2647626

Sources:
ChemblInteractions
DACLIZUMAB IL2RA

Interaction Score: 5.33

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources:
TdgClinicalTrial ChemblInteractions TEND
DACLIZUMAB IL2RG

Interaction Score: 3.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DACLIZUMAB IL2

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

TEND: DACLIZUMAB
- Version: 01-August-2011
Alternate Names:

DACLIZUMAB Primary Drug Name

Drug Info:

Drug Class immunosuppressive agents

Year of Approval 1997

Publications:
TdgClinicalTrial: DACLIZUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications immunosuppressant

Drug Class monoclonal antibody

FDA Approval approved

Publications:
TTD: Daclizumab
- Version: 2020.06.01
Alternate Names:

D0P1BZ TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201605
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201605
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Interleukin-2 receptor inhibitor
Direct Interaction	yes

antibody (inhibitory)
inhibitor (inhibitory)

antibody (inhibitory)
inhibitor (inhibitory)

DACLIZUMAB Drug Record

DACLIZUMAB chembl:CHEMBL1201605 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

DACLIZUMAB IL2RB

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes

PMIDs: 15814281 15022409 12372041 2571203 11752352 2647626

Sources: ChemblInteractions

DACLIZUMAB IL2RA

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes Novel drug target Established target

PMIDs: 16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources: TdgClinicalTrial ChemblInteractions TEND

DACLIZUMAB IL2RG

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Interleukin-2 receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

DACLIZUMAB IL2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TEND: DACLIZUMAB

Alternate Names: DACLIZUMAB Primary Drug Name

Drug Info: Drug Class immunosuppressive agents Year of Approval 1997

Publications:

TdgClinicalTrial: DACLIZUMAB

Alternate Names:

Drug Info: Drug Indications immunosuppressant Drug Class monoclonal antibody FDA Approval approved

Publications:

TTD: Daclizumab

Alternate Names: D0P1BZ TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201605

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201605

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
15814281 15022409 12372041 2571203 11752352 2647626

Sources:
ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
16908318 19788505 16304857 11752352 8600944 10607689 17564638

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Interleukin-2 receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Alternate Names:

DACLIZUMAB Primary Drug Name

Drug Info:

Drug Class immunosuppressive agents

Year of Approval 1997

Drug Info:

Drug Indications immunosuppressant

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

D0P1BZ TTD Drug ID